Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

New Risk Score Promising for Predicting MI, Death

Clinical chemistry score based on cardiac troponin, glucose level, estimated glomerular filtration rate

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

THURSDAY, Sept. 13, 2018 (HealthDay News) -- A score based on the results of three laboratory tests has higher sensitivity and specificity than cardiac troponin alone for stratifying patients presenting with suspected acute coronary syndrome, according to a study published online Aug. 19 in CMAJ, the journal of the Canadian Medical Association.

Peter A. Kavsak, Ph.D., from McMaster University in Hamilton, Canada, and colleagues constructed a clinical chemistry score (CCS; range, 0 to 5 points) based on high-sensitivity cardiac troponin (hs-cTn), glucose level, and estimated glomerular filtration rate test results. The score was validated as a predictor of 30-day myocardial infarction (MI) or death using data from four cohorts involving 4,245 patients who presented to the emergency department with symptoms suggestive of acute coronary syndrome. A total of 17.1 percent of participants had an MI or died within 30 days.

The researchers found that low-risk patients were best identified with a CCS score of 0 points. High-sensitivity cardiac troponin I (hs-cTnI) CCS had a sensitivity of 100 percent, with 8.9 percent of the population classified as low risk of MI or death within 30 days; high-sensitivity cardiac troponin T (hs-cTnT) CCS had a sensitivity of 99.9 percent, with 10.5 percent of the population classified as low-risk. The CCS had better sensitivity than hs-cTn alone. High-risk patients were best identified with a CCS score of 5 points (hs-cTnI CCS: specificity, 96.6 percent with 11.2 percent of the population classified as high-risk; hs-cTnT CCS: specificity, 94 percent and 13.1 percent of the population classified as high risk) versus using the overall 99th percentiles for the hs-cTn assays (specificity of hs-cTnI, 93.2 percent; specificity of hs-cTnT, 73.8 percent).

"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors," Kavsak said in a statement.

Several authors disclosed financial ties to pharmaceutical companies, including Abbott Laboratories and Roche Diagnostics, which provided reagent support for the study. Two authors have a pending patent application on a risk stratification score for patients with possible cardiac injury.

Abstract/Full Text

Last Updated: